[Mutation of EGFR signaling pathway and therapy for metastatic colorectal cancer]
- PMID: 20495308
[Mutation of EGFR signaling pathway and therapy for metastatic colorectal cancer]
Abstract
For the patient in whom the Kras gene variation appears, cancer cell grow and continue to multiply even if blocked by EGFR inhibitor. A topping the offered figure effect of cetuximab is not accepted. The addition of cetuximab for treatment of metastatic colorectal cancer with Kras wild-type tumors is effective.
Similar articles
-
KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature.J Clin Oncol. 2008 May 1;26(13):2228-30; author reply 2230-1. doi: 10.1200/JCO.2007.15.9186. J Clin Oncol. 2008. PMID: 18445856 No abstract available.
-
To give or not to give anti-epidermal growth factor receptor (EGFR) monoclonal antibodies to patients with KRAS G13D mutation in advanced colorectal cancer.Clin Colorectal Cancer. 2012 Jun;11(2):85-7. doi: 10.1016/j.clcc.2011.10.005. Epub 2011 Dec 9. Clin Colorectal Cancer. 2012. PMID: 22169039 Review. No abstract available.
-
Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.Ann Surg. 2010 Feb;251(2):254-60. doi: 10.1097/SLA.0b013e3181bc9d96. Ann Surg. 2010. PMID: 20010090
-
Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.Cancer Treat Rev. 2009 May;35(3):262-71. doi: 10.1016/j.ctrv.2008.11.005. Epub 2008 Dec 30. Cancer Treat Rev. 2009. PMID: 19117687 Review.
-
[Cetuximab for patients with metastatic colorectal cancer-from the result of recent clinical trials].Gan To Kagaku Ryoho. 2010 May;37(5):782-6. Gan To Kagaku Ryoho. 2010. PMID: 20495306 Japanese.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous